Author(s)

Marcio Debiasi^1,2*, Franklin Fernandes Pimentel³, Paula Juliana Seadi Pereira⁴, Carlos H. Barrios^2,5

¹Medical Oncology Division, Internal Medicine Department, PUCRS School of Medicine, Porto Alegre, Brazil.
²LACOG (Latin American Cooperative Oncology Group), Porto Alegre, Brazil.
³Breast Disease Division, Department of Gynecology and Obstetrics, Ribeirao Preto Medical School, University of Sao Paulo, Sao Paulo, Brazil.
⁴Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
⁵Hospital do Cancer Mae de Deus, Porto Alegre, Brazil.

Cancer is a major public health issue worldwide, especially in the developing world where 70% of the cancer-related deaths occur. During the last three decades, with the advent of targeted therapies using monoclonal antibodies, patients’ survival and quality of life have dramatically improved. Unfortunately, these great accomplishments came at the expense of high financial costs which most of the population living in low-and middle-income countries cannot afford. Biosimilars (biotherapeutic products that are similar to an already licensed reference biotherapeutic product in terms of quality, safety and efficacy) have been successfully used in Europe and in US with a substantial reduction in price of around 30%. Brazil is about to have trastuzumab as the first biosimilar available to treat cancer patients in the country. Based on strict regulatory legislations, biosimilars are expected to deliver affordable yet effective and safe treatment options all over the world, expanding the access to cancer treatment and reducing inequalities.

Cancer Therapy, Biosimilar, Trastuzumab, Herceptin, Breast Cancer

Debiasi, M. , Pimentel, F. , Pereira, P. and Barrios, C. (2017) Biosimilars in Brazil: The Beginning of an Era of Broader Access. Journal of Cancer Therapy, 8, 814-826. doi: 10.4236/jct.2017.89071.